Email this article Expert council resolution on treatment of patients with metastatic colorectal cancer
- Issue: Vol 8, No 3 (2018)
- Pages: 51-53
- Section: MESSAGE FOR THE EDITORIAL BOARD
- Published: 03.11.2018
- URL: https://onco-surgery.info/jour/article/view/261
- DOI: https://doi.org/undefined
- ID: 261
Cite item
Full Text
Abstract
.
References
- Fedyanin M.Yu., Alieva Sh.A., Vladimirova L.Yu. et al. Quality of treatment for metastatic colon cancer in routine clinical practice. Zlokachestvennye opukholi = Malignant Tumors 2017;7(3 special issue 1):4–11. (In Russ.).
- Kopetz S., Chang G.J., Overman M.J. et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27(22):3677–83. PMID: 19470929. doi: 10.1200/JCO.2008.20.5278.
- Adam R., Yi B., Innominato P.F. et al. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer 2017;78:7–15. PMID: 28407529. doi: 10.1016/j.ejca.2017.03.009.
- Adam R., ASCO 2012, abstract 3521.
- Garufi C., Torsello A., Tumolo S. et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010;103(10):1542–7. PMID: 20959822. doi: 10.1038/sj.bjc.6605940.
- Folprecht G. et al. EMCC 2011, abstract 6009.
- Köhne C.-H. et al. ASCO 2011, abstract 3576. 8. Modest D.P., Denecke T., Pratschke J. et al. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancercentral evaluation of FIRE-3. Eur J Cancer 2018;88:77–86. PMID: 29195117. doi: 10.1016/j.ejca.2017.10.028.
- Stintzing S., Modest D.P., Rossius L. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wildtype subgroup of this randomised openlabel phase 3 trial. Lancet Oncol 2016;17(10):1426–34. PMID: 27575024. doi: 10.1016/S1470-2045(16)30269-8.
- Petrelli F., Ardito R., Ghidini A. et al. Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and metaanalysis. Oncology 2018;94(4):191–9. PMID: 29393280. doi: 10.1159/000486338.
- Price T., Kim T.W., Li J. et al. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemo-refractory wildtype KRAS exon 2 metastatic colorectal cancer. Eur J Cancer 2016;68:51–9. PMID: 27716478. doi: 10.1016/j.ejca.2016.08.010.
- NCCN Guidelines v. 3, 2018. Colon cancer.
Supplementary files
